Trinity Biotech (TRIB) Total Non-Current Liabilities (2009 - 2025)

Trinity Biotech has reported Total Non-Current Liabilities for 17 years, with the latest figure at $35.9 million in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 66.22% year-over-year to $35.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.9 million (down 66.22% YoY) and the FY2025 annual result came in at $35.9 million, down 66.22% from the prior year.
• Total Non-Current Liabilities retreated to $35.9 million in Q4 2025 per TRIB's latest filing, from $117.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $117.6 million in Q2 2025 and troughed at $18.7 million in Q4 2021.
• A 5-year average of $73.3 million and a median of $77.2 million in 2022 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities sank 82.26% in 2021, then jumped 310.94% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $18.7 million in 2021, then soared by 310.94% to $76.9 million in 2022, then retreated by 11.17% to $68.3 million in 2023, then surged by 55.64% to $106.4 million in 2024, then tumbled by 66.22% to $35.9 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $35.9 million, $117.6 million, and $106.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.